Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status

Chan Woo Wee, Eunji Kim, Nalee Kim, In Ah Kim, Tae Min Kim, Yu Jung Kim, Chul Kee Park, Jin Wook Kim, Chae Yong Kim, Seung Hong Choi, Jae Hyoung Kim, Sung Hye Park, Gheeyoung Choe, Soon Tae Lee, Jong Hee Chang, SeHoon Kim, Chang-Ok Suh, Il Han Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and purpose To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. Methods and Materials Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4% and 6.2% of the patients, respectively. Results The median follow-up for survivors and all patients was 33.2 and 20.5 months, respectively. The median survival (MS) was 23.6 months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I = MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS ≥ 90 (MS, 67.2 months); class II = MGMTmeth/IDH1wt/GTR/KPS < 90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age < 50, or MGMTunmeth/age ≥ 50/GTR (MS, 24.0 months); class III = MGMTunmeth/age ≥ 50/residual disease (MS, 15.2 months). Conclusions A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalRadiotherapy and Oncology
Volume123
Issue number1
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Glioblastoma
Methylation
temozolomide
Mutation
Survival
Genes
Proportional Hazards Models
Tertiary Care Centers
Survivors
Radiotherapy
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Wee, Chan Woo ; Kim, Eunji ; Kim, Nalee ; Kim, In Ah ; Kim, Tae Min ; Kim, Yu Jung ; Park, Chul Kee ; Kim, Jin Wook ; Kim, Chae Yong ; Choi, Seung Hong ; Kim, Jae Hyoung ; Park, Sung Hye ; Choe, Gheeyoung ; Lee, Soon Tae ; Chang, Jong Hee ; Kim, SeHoon ; Suh, Chang-Ok ; Kim, Il Han. / Novel recursive partitioning analysis classification for newly diagnosed glioblastoma : A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. In: Radiotherapy and Oncology. 2017 ; Vol. 123, No. 1. pp. 106-111.
@article{0c2e7b29806e4394b71ce747807c461b,
title = "Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status",
abstract = "Background and purpose To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. Methods and Materials Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4{\%} and 6.2{\%} of the patients, respectively. Results The median follow-up for survivors and all patients was 33.2 and 20.5 months, respectively. The median survival (MS) was 23.6 months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I = MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS ≥ 90 (MS, 67.2 months); class II = MGMTmeth/IDH1wt/GTR/KPS < 90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age < 50, or MGMTunmeth/age ≥ 50/GTR (MS, 24.0 months); class III = MGMTunmeth/age ≥ 50/residual disease (MS, 15.2 months). Conclusions A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.",
author = "Wee, {Chan Woo} and Eunji Kim and Nalee Kim and Kim, {In Ah} and Kim, {Tae Min} and Kim, {Yu Jung} and Park, {Chul Kee} and Kim, {Jin Wook} and Kim, {Chae Yong} and Choi, {Seung Hong} and Kim, {Jae Hyoung} and Park, {Sung Hye} and Gheeyoung Choe and Lee, {Soon Tae} and Chang, {Jong Hee} and SeHoon Kim and Chang-Ok Suh and Kim, {Il Han}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.radonc.2017.02.014",
language = "English",
volume = "123",
pages = "106--111",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Wee, CW, Kim, E, Kim, N, Kim, IA, Kim, TM, Kim, YJ, Park, CK, Kim, JW, Kim, CY, Choi, SH, Kim, JH, Park, SH, Choe, G, Lee, ST, Chang, JH, Kim, S, Suh, C-O & Kim, IH 2017, 'Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status', Radiotherapy and Oncology, vol. 123, no. 1, pp. 106-111. https://doi.org/10.1016/j.radonc.2017.02.014

Novel recursive partitioning analysis classification for newly diagnosed glioblastoma : A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. / Wee, Chan Woo; Kim, Eunji; Kim, Nalee; Kim, In Ah; Kim, Tae Min; Kim, Yu Jung; Park, Chul Kee; Kim, Jin Wook; Kim, Chae Yong; Choi, Seung Hong; Kim, Jae Hyoung; Park, Sung Hye; Choe, Gheeyoung; Lee, Soon Tae; Chang, Jong Hee; Kim, SeHoon; Suh, Chang-Ok; Kim, Il Han.

In: Radiotherapy and Oncology, Vol. 123, No. 1, 01.04.2017, p. 106-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel recursive partitioning analysis classification for newly diagnosed glioblastoma

T2 - A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status

AU - Wee, Chan Woo

AU - Kim, Eunji

AU - Kim, Nalee

AU - Kim, In Ah

AU - Kim, Tae Min

AU - Kim, Yu Jung

AU - Park, Chul Kee

AU - Kim, Jin Wook

AU - Kim, Chae Yong

AU - Choi, Seung Hong

AU - Kim, Jae Hyoung

AU - Park, Sung Hye

AU - Choe, Gheeyoung

AU - Lee, Soon Tae

AU - Chang, Jong Hee

AU - Kim, SeHoon

AU - Suh, Chang-Ok

AU - Kim, Il Han

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background and purpose To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. Methods and Materials Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4% and 6.2% of the patients, respectively. Results The median follow-up for survivors and all patients was 33.2 and 20.5 months, respectively. The median survival (MS) was 23.6 months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I = MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS ≥ 90 (MS, 67.2 months); class II = MGMTmeth/IDH1wt/GTR/KPS < 90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age < 50, or MGMTunmeth/age ≥ 50/GTR (MS, 24.0 months); class III = MGMTunmeth/age ≥ 50/residual disease (MS, 15.2 months). Conclusions A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.

AB - Background and purpose To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. Methods and Materials Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4% and 6.2% of the patients, respectively. Results The median follow-up for survivors and all patients was 33.2 and 20.5 months, respectively. The median survival (MS) was 23.6 months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I = MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS ≥ 90 (MS, 67.2 months); class II = MGMTmeth/IDH1wt/GTR/KPS < 90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age < 50, or MGMTunmeth/age ≥ 50/GTR (MS, 24.0 months); class III = MGMTunmeth/age ≥ 50/residual disease (MS, 15.2 months). Conclusions A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=85014845008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014845008&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2017.02.014

DO - 10.1016/j.radonc.2017.02.014

M3 - Article

C2 - 28302331

AN - SCOPUS:85014845008

VL - 123

SP - 106

EP - 111

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -